08.25.16
Amar Thyagarajan, Ph.D., has been appointed associate director of product marketing and strategy, and Sandeep Sinha, Ph.D., has been named scientific director, Crown Bioscience.
Dr. Thyagarajan brings extensive scientific and senior product management experience with genetically engineered models used in neuroscience and cardiovascular and metabolic disease (CVMD) drug discovery and safety and toxicology studies. He is responsible for the strategic and scientific marketing of CrownBio’s CVMD portfolio.
“With Amar’s acumen for developing market strategies, he will enhance our marketing communications and presence for our growing line of CVMD models and services to support drug development,” said Laurie Heilmann, senior vice president of global strategy, marketing and business development at CrownBio.
Dr. Sinha is responsible for leading CrownBio’s technical teams to build better partnerships with clients for successful CVMD programs.
Prior to joining CrownBio, Dr. Sinha worked at Eli Lilly as a medical science liaison for diabetes and cardiovascular disease.
“CrownBio is committed to hiring experienced and knowledgeable industry leaders to advance our CVMD services to benefit our clients, and we are pleased to add these talented individuals to our team,” said Ms. Heilmann.
Dr. Thyagarajan brings extensive scientific and senior product management experience with genetically engineered models used in neuroscience and cardiovascular and metabolic disease (CVMD) drug discovery and safety and toxicology studies. He is responsible for the strategic and scientific marketing of CrownBio’s CVMD portfolio.
“With Amar’s acumen for developing market strategies, he will enhance our marketing communications and presence for our growing line of CVMD models and services to support drug development,” said Laurie Heilmann, senior vice president of global strategy, marketing and business development at CrownBio.
Dr. Sinha is responsible for leading CrownBio’s technical teams to build better partnerships with clients for successful CVMD programs.
Prior to joining CrownBio, Dr. Sinha worked at Eli Lilly as a medical science liaison for diabetes and cardiovascular disease.
“CrownBio is committed to hiring experienced and knowledgeable industry leaders to advance our CVMD services to benefit our clients, and we are pleased to add these talented individuals to our team,” said Ms. Heilmann.
